BactiQuant Plans Private Placement to Raise Up to DKK 8.3 Million
Bitget2026/10/20 15:11- Bactiquant plans a private placement to raise up to approximately DKK 8.3 million in gross proceeds.
- Shares will be offered at the average market price over the past 10 days, without existing shareholders’ preemptive rights.
- The placement is expected to be completed within days; registration and trading of new shares will follow later.
- Proceeds will primarily replenish liquidity following repayment of a DKK 9.2 million EIFO loan on September 30, 2026.
- The loan repayment is expected to improve annual liquidity by nearly DKK 2 million, including interest savings.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
CleanSpark presents fully funded Sandersville project in investor presentation
Forge Nano completes acquisition of HzO
Crypto prices
More
